- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
Patent holdings for IPC class A61K 31/45
Total number of patents in this class: 540
10-year publication summary
20
|
32
|
48
|
55
|
42
|
38
|
42
|
42
|
45
|
12
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Celgene Corporation | 1419 |
20 |
Amicus Therapeutics, Inc. | 349 |
18 |
Dana-Farber Cancer Institute, Inc. | 2529 |
11 |
Bristol-myers Squibb Company | 4848 |
9 |
Boehringer Ingelheim International GmbH | 4732 |
8 |
Amgen Inc. | 3985 |
7 |
Novartis AG | 11042 |
6 |
The Regents of the University of California | 19681 |
6 |
Bpcr Limited Partnership | 37 |
6 |
Allergan, Inc. | 2372 |
5 |
Baylor College of Medicine | 926 |
5 |
Cambridge Enterprise Limited | 1171 |
5 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. | 913 |
5 |
C4 Theraprutics, Inc. | 56 |
5 |
F. Hoffmann-La Roche AG | 7889 |
4 |
The Johns Hopkins University | 5575 |
4 |
C4 Therapeutics, Inc. | 86 |
4 |
Eli Lilly and Company | 3773 |
4 |
Epizyme, Inc. | 367 |
4 |
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises" | 31 |
4 |
Other owners | 400 |